Ligand Pharmaceuticals Inc
LGNDHealthcare|Biotechnology|USA
$316.24
-6.50 (-2.01%)
DCF (FCF)
$71.09
Tangible Book
$33.87
Graham Number
$79.73
Earnings Power
$30.25
Clinical Trials (41)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT00211198 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | Lymphoma, T-Cell, Cutaneous | P4 | Completed | 60 | Open-label | ONTAK (denileukin difitox, DAB389IL-2) |
| NCT01128959 Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy | Epilepsy | P3 | Completed | 108 | Open-label | Intravenous Carbamazepine (IV CBZ) |
| NCT00163137 Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss | Osteoporosis | P3 | Completed | 540 | RCT, Double-blind | lasofoxifene, raloxifene, Placebo |
| NCT00141323 Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) | Osteoporosis | P3 | Completed | 8,556 | RCT, Double-blind | lasofoxifene, lasofoxifene |
| NCT00063076 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata | Alopecia Areata | P2P3 | Completed | 46 | RCT, Open-label | Targretin Gel 1% |
| NCT04627831 Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography | Contrast-induced Nephropathy | P2 | Withdrawn | — | RCT, Double-blind | CE-Iohexol, Iohexol |
| NCT00125359 Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | Carcinoma, Non-small-cell Lung | P2 | Completed | 42 | Open-label | erlotinib and bexarotene |
| NCT00153842 A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer | Carcinoma, Non-small-cell Lung | P1P2 | Terminated | 33 | Open-label | Bexarotene (targretin), Bexarotene (targretin) |
| NCT02851849 A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P2 | Completed | 148 | RCT, Double-blind | LGD-6972-5 mg, LGD-6972-10 mg, LGD-6972-15 mg |
| NCT00879112 Study of MB07811 in Subjects With Hypercholesterolemia | Hypercholesterolemia | P2 | Withdrawn | 80 | RCT, Double-blind | MB07811, Placebo |
| NCT00002212 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma | Sarcoma, Kaposi, HIV Infections | P2 | Completed | 27 | — | Bexarotene |
| NCT00635232 A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension | Hypertension | P2 | Completed | 261 | RCT, Double-blind | irbesartan, placebo, PS433540, PS433540, PS433540 |
| NCT00940953 Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis | Seasonal Allergic Rhinitis | P2 | Completed | 108 | RCT, Double-blind | Budesonide + Azelastine, Budesonide + Azelastine, Placebo |
| NCT00938613 Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR | Seasonal Allergic Rhinitis | P2 | Completed | 65 | RCT, Double-blind | Budesonide, Placebo, Budesonide |
| NCT00151008 Bexarotene With Narrow-Band UVB for Psoriasis | Psoriasis | P2 | Completed | 35 | RCT, Double-blind | Bexarotene/NBUVB vs placebo NBUVB |
| NCT00306969 Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma | Cutaneous T-Cell Lymphoma | P1P2 | Completed | 18 | Open-label | bexarotene |
| NCT00143273 Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation | Osteoporosis | P2 | Completed | 497 | RCT, Double-blind | lasofoxifene, Placebo, Lasofoxifene, Lasofoxifene |
| NCT00238628 A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | Lung Cancer | P1P2 | Completed | 6 | Open-label | Bexarotene, Iressa |
| NCT00623324 The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease | Early Stage Parkinson's Disease | P2 | Completed | 40 | RCT, Double-blind | Aplindore, Placebo |
| NCT00322296 Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis | Parapsoriasis | P2 | Terminated | 8 | Open-label | Bexarotene 1% gel |
| NCT00626418 The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome | Restless Legs Syndrome | P2 | Completed | 24 | RCT, Single-blind | Aplindore, Placebo |
| NCT00002188 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma | Sarcoma, Kaposi, HIV Infections | P2 | Completed | 27 | — | Alitretinoin |
| NCT00006345 Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma | Drug/Agent Toxicity by Tissue/Organ, Lymphoma | P2 | Completed | — | — | denileukin diftitox, dexamethasone |
| NCT00003752 Bexarotene in Treating Patients With Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 180 | RCT | bexarotene |
| NCT00073736 Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1P2 | Completed | 28 | Open-label | MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day, MB07133 1800 mg/m2/day, MB07133 2400 mg/m2/day |
| NCT00522925 A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension | Hypertension | P2 | Completed | 280 | RCT, Double-blind | PS433540, placebo, PS433540 |
| NCT00458016 Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P2 | Completed | 105 | RCT, Double-blind | MB07803, Placebo |
| NCT00674453 The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation | Bone Loss | P2 | Completed | 51 | RCT, Double-blind | Lasofoxifene |
| NCT02672839 A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation | Type 2 Diabetes Mellitus (T2DM) | P1 | Completed | 12 | RCT, Open-label | LGD-6972 Solution, LGD-6972 Capsules |
| NCT01116622 Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | P1 | Completed | 24 | Open-label | Bexarotene (Targretin®), Erlotinib (Tarceva™) |
| NCT04629976 Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B | Chronic Hepatitis B | P1 | Completed | 21 | RCT, Open-label | NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg |
| NCT04309526 Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects | Hepatitis B | P1 | Completed | 48 | RCT, Double-blind | NCO-48 Fumarate, Placebo |
| NCT01919684 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P1 | Completed | 56 | RCT, Double-blind | LGD-6972, Placebo (Captisol®) |
| NCT05685277 Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions | Bioequivalence | P1 | Completed | 50 | RCT, Single-blind | Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg, Tritace® Plus tablet 10 mg/25 mg |
| NCT02250222 Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P1 | Completed | 48 | RCT, Double-blind | LGD-6972, Placebo (Captisol ®) |
| NCT05438316 Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions | Bioequivalence | P1 | Completed | 50 | RCT, Single-blind | Ramipril tablet 10 mg, Tritace® tablet 10 mg |
| NCT00125372 Study of Tarceva and Targretin in Stage I-II Lung Cancer | Carcinoma, Non-small-cell Lung | N/A | Completed | 12 | Open-label | erlotinib (Tarceva) and bexarotene (Targretin) |
| NCT03869983 Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection | Contrast-induced Nephropathy, Coronary Angiography | N/A | Completed | 24 | RCT, Double-blind | — |
| NCT05707494 Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis | Sepsis, Septic Shock | N/A | Completed | 78 | Open-label | — |
| NCT00002439 A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma | Sarcoma, Kaposi, HIV Infections | N/A | Completed | — | — | Alitretinoin |
| NCT04827407 Lipopolysaccharide Adsorption At Septic Shock | Septic Shock | N/A | Completed | 58 | RCT, Open-label | — |